alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

30,180 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 526–550 of 559 studies · free to read (page 22 of 23) · 30,180 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Showing 559 studies tagged small — clear

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 15,654 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Targeting CD38 to alleviate brain endothelial cell dysfunction and cognitive impairment in vascular dementia

✓ Peer-reviewed alzhub usefulness score 36 out of 100. Journal of Pharmacological Sciences 2025-05-21

Vascular dementia (VaD) is a leading cause of cognitive decline, closely associated with cerebrovascular endothelial cell (CEC) dysfunction, blood-brain barrier (BBB) disruption, and neuroinflammation. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Elucidating molecular pathogenesis and developing targeted therapeutic interventions for cerebrovascular endothelial cell-mediated vascular dementia

✓ Peer-reviewed alzhub usefulness score 36 out of 100. Frontiers in Aging Neuroscience 2025-07-16

Vascular dementia (VaD) ranks as the second most prevalent subtype of dementia, surpassed only by Alzheimer's disease (AD). 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Cerebral Small Vessel Disease: Current and Emerging Therapeutic Strategies

✓ Peer-reviewed alzhub usefulness score 36 out of 100. Aging and Disease 2025-01-01

Cerebral small vessel disease (CSVD) is a common disease in older people, characterized by damage to intracranial microvessels, leading to cognitive decline, increased risk of stroke, and dementia. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

An exploratory study of the diffusion tensor imaging analysis along perivascular spaces (DTI-ALPS) index combined with quantitative analysis of choroid plexus volume and perivascular spaces in different cognitive stages of cerebral small vessel disease

✓ Peer-reviewed alzhub usefulness score 36 out of 100. Quantitative Imaging in Medicine and Surgery 2025-08-21

NCs/CSVD-CN: AUC =0.900, 95% CI: 0.847-0.952. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Metabolic and vascular contributions to dementia: Soluble epoxide hydrolase‐derived linoleic acid oxylipins and glycemic status are related to cerebral small vessel disease markers, atrophy, and cognitive performance

✓ Peer-reviewed alzhub usefulness score 36 out of 100. Alzheimer s & Dementia 2025-10-01

With elevated HbA1c, greater LA-derived diol/epoxide ratios were associated with greater WMH volume (β [95% CI] = 0.565 [0.100, 1.030], p = 0.017), lower global BPF (β [95% CI] = -0.476 [-0.903, -0.048], p = 0.029), and poorer memory performance (β [95% CI] = -0.603 [-1.070, -0.136], p = 0.012), such that detrimental associations were observed only in T2DM. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Mitochondrial Reactive Oxygen Species Production in Vascular Dementia Following Experimental Diabetes

✓ Peer-reviewed alzhub usefulness score 35 out of 100. Cells 2025-08-15

Type 1 diabetes (T1D) is a serious disease which affects millions of people worldwide and is a major factor for vascular contributions to cognitive impairment and dementia (VCID). 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Healthy dietary intake diminishes the effect of cerebral small vessel disease on cognitive performance in older adults

✓ Peer-reviewed alzhub usefulness score 35 out of 100. Frontiers in Neurology 2025-03-06

Dietary intake moderated the association between several cSVD biomarkers and MoCA scores such that the expected negative association between cSVD biomarkers and cognition was seen at low levels of healthy dietary intake, but not at medium or high levels. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Greater White Matter Hyperintensities and More Severe Cognitive Dysfunction in Mild Cognitive Impairment With Motoric Cognitive Risk Syndrome

✓ Peer-reviewed alzhub usefulness score 35 out of 100. Journal of Korean Medical Science 2025-01-01

< 0.0036), the MCRS group exhibited significantly worse performance on word list memory, word list recall, and MMSE-KC compared to the MCI group without slow gait. 2 key findings →

Participants: 81 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Impact of PM2.5 on Cardiovascular Disease, Dementia, and Stroke in Older Kidney Transplant Recipients

✓ Peer-reviewed alzhub usefulness score 34 out of 100. American Journal of Transplantation 2025-01-01

Exposure to fine particulate matter (PM ) pollution is associated with negative health outcomes including dementia, cardiovascular disease (CVD), and stroke due to increased levels of oxidative stress and inflammation among community-dwelling older adults. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The impact of moxibustion on brain function in vascular dementia: a neuroimaging study involving amplitude of low-frequency fluctuations and functional connectivity

✓ Peer-reviewed alzhub usefulness score 32 out of 100. Frontiers in Neurology 2025-12-18

Object On the basis of determining the clinical effect of moxibustion on vascular dementia (VD), this study explored the central mechanism of moxibustion on VD through fMRI. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Retinal vessel density using optical coherence tomography angiography as a potential biomarker in patients with cerebral small vessel disease

✓ Peer-reviewed alzhub usefulness score 32 out of 100. The Egyptian Journal of Neurology Psychiatry and Neurosurgery 2025-05-26

OCTA is a handy, noninvasive tool that enables the visualization of diminished retinal microvascular density in cases of early CSVD. 3 key findings →

Participants: 40 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled.

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 30,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 30,180 records, built mostly from automated pulls of Europe PMC (64.2% of the library) and OpenAlex (16.9%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,037 records (3.4% of the library) are not peer-reviewed — 964 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed